AI assistant
CSL Ltd. — M&A Activity 2006
Dec 17, 2006
17854_rns_2006-12-17_d9377fd1-f4a0-4cc7-80aa-27aa12f81060.pdf
M&A Activity
Open in viewerOpens in your device viewer
T +613 9389 1911
F +613 9389 1434 www.csl.com.au
CSL Limited 45 Poplar Road Parkville Victoria 3052 Australia
ASX Announcement
For immediate release
December 18, 2006
CSL Completes acquisition of CytoGam® From MedImmune
Melbourne Australia: CSL Limited announced today that its subsidiary, ZLB Behring, has completed its purchase of CytoGam® (cytomegalovirus immunoglobulin intravenous (human)) and telated assets from MedImmune, Inc. CytoGam is an intravenous immunoglobulin enriched in antibodies against cytomegalovirus (CMV), which is indicated for preventing CMV discase associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is the most common cause of life-threatening infection occurring in solid organ transplants.
ZLB Behring paid U.S. \$120 million in cash, \$70 million of which is subject to achievement of sales milestones. ZLB Behring manufactures immunoglobulins and other plasmaderived therapies, and markets them in more than 100 countries.
The acquisition includes CytoGam and related assets, including trademarks, manufacturing contracts and government authorizations associated with the product.
For more information about CSL Limited, visit www.csl.com.au
For further information please contact:
Media Contacts
Australia and New Zealand Dr Rachel David Director of Public Affairs Phone: 0401 775 779
Investor Contact
Mark Dehring Director of Investor Relations Phone: +61 3 9389 2818 E-mail: [email protected]